Sedative, Hypnotic, and Anxiolytic Use Disorders

Sedatives, Hypnotics, Anxiolytics - The Chill Pill Problem

SHAs are psychoactive drugs that depress Central Nervous System (CNS) function, widely used for therapeutic purposes but with high abuse potential.

• Sedatives: Reduce excitement, induce calmness.
• Hypnotics: Primarily induce or maintain sleep.
• Anxiolytics: Specifically reduce anxiety.

⭐ Benzodiazepines are the most commonly abused prescription drugs in this class, often initiated for legitimate medical reasons.

SHA Pharmacology - Brain on Brakes

• Mechanism: Enhance GABA at GABA-A receptors → ↑ Cl- influx → hyperpolarization.
• BZDs: ↑ FREquenZy of Cl- channel opening (GABA-dependent). 📌 BenZos!
• Barbiturates: ↑ DURATion of Cl- channel opening. High doses: direct opening. 📌 BarbiDURATes!
• Kinetics:
  • Lipid solubility: ↑ solubility → faster onset.
  • Half-life: Short (↑ abuse/withdrawal severity), intermediate, long (smoother withdrawal).

⭐ Barbiturates increase GABA-A Cl- channel opening duration (direct at high doses); BZDs increase frequency (GABA needed).

SHA Intoxication - Too Much Calm

• Clinical Features: Slurred speech, incoordination, ataxia, nystagmus, ↓cognition, stupor/coma, respiratory depression.
• Diagnosis: Clinical; urine toxicology.
• Overdose Comparison:

  Feature	Benzodiazepines (BZD)	Barbiturates
  Resp. Depression	Mild (severe if +others)	Severe
  CVS Effects	Minimal	Hypotension, shock
  Flumazenil	Yes (cautious)	No

⭐ Flumazenil: precipitates seizures in chronic BZD users/TCA co-ingestion. Not for resp. depression if other depressants involved.

SHA Withdrawal - Rebound Storm

CNS hyperexcitability due to abrupt cessation/reduction. Onset/duration varies:

• Barbiturate Withdrawal: Generally more dangerous than BZD withdrawal; higher risk of hyperthermia, cardiovascular collapse, status epilepticus.
• Assessment: CIWA-B (Benzodiazepines). Score >10 may need medication.
• Management:
  • Principle: Gradual taper (10-25% every 1-2 weeks).
  • Substitution: Convert to equivalent long-acting BZD (Diazepam, Chlordiazepoxide). Phenobarbital for barbiturate or severe/refractory BZD withdrawal.

⭐ Withdrawal from high-dose, short-acting BZDs or barbiturates can be life-threatening, with seizures (typically 2-8 days after cessation for BZDs) and delirium being major concerns.

SHA Dependence Treatment - Breaking Free

• Diagnosis: Based on DSM-5 criteria for SHA Use Disorder.
• Detoxification: Cornerstone is a slow, gradual taper.

  ⭐ A slow, gradual taper (e.g., reducing equivalent daily diazepam dose by 10-25% every 1-2 weeks, or slower for long-term high-dose users) is crucial for managing benzodiazepine dependence to minimize withdrawal severity and improve success rates.

• Pharmacological: Limited role; anticonvulsants for protracted withdrawal.
• Psychosocial Interventions: CBT, motivational interviewing, group & family therapy.
• Relapse Prevention: Key for sustained recovery.

High‑Yield Points - ⚡ Biggest Takeaways

• Benzodiazepines (BZDs) and Barbiturates are primary sedative-hypnotics.
• BZDs ↑ GABA-A channel opening frequency; Barbiturates ↑ duration of opening.
• Intoxication features CNS depression, slurred speech, ataxia; respiratory depression risk ↑ with alcohol.
• Withdrawal syndrome: anxiety, insomnia, tremors, autonomic hyperactivity, seizures (life-threatening).
• Flumazenil is the antidote for BZD overdose; supportive care for barbiturates.
• Barbiturate withdrawal is generally more severe than BZD withdrawal.
• Significant cross-tolerance exists with alcohol and other CNS depressants.